COVID-19 疫苗接种后的不良反应：系统评价和荟萃分析。

Adverse events following COVID-19 vaccination: A systematic review and meta-analysis.

机构信息

Tropical and Infectious Diseases Department, Zahedan University of Medical Sciences, Zahedan, Iran; Zahedan University of Medical Sciences Research Center, Emam Ali Hospital, Zahedan, Iran.

Health Promotion Research Center, Department of Epidemiology and Biostatistics, Zahedan University of Medical Sciences, Zahedan, Iran.

出版信息

Int Immunopharmacol. 2022 Aug;109:108906. doi: 10.1016/j.intimp.2022.108906. Epub 2022 May 30.

DOI:10.1016/j.intimp.2022.108906

PMID:35671640

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9148928/

Abstract

BACKGROUND

High speed of COVID-19 vaccination has raised some concerns about the safety of the new vaccines. It is of a great importance to perform a review of the safety and efficacy of the COVID-19 vaccines.

METHODS

Two International electronic databases (PubMed, ISI) were searched for clinical trials reporting efficacy and safety of COVID-19 vaccines compared to control group. Pooled risk ratio (RR) for total, systemic and local adverse events following immunization was calculated for different vaccine modalities.

RESULTS

The pooled RRs of total adverse reactions for Inactivated, mRNA, and vector vaccines were 1.46 (95% CI: 1.19-1.78), 2.01 (95% CI: 1.82 - 2.23), and 1.65 (95% CI: 1.31 - 2.32) respectively. The pooled RR for occurrence of systemic adverse reactions following immunization for different vaccine modalities was 1.13 (95% CI: 0.79 - 1.61), 1.53 (95% CI 1.08 - 2.16), 1.58 (95% CI: 1.13 - 1.90), 0.72 (95% CI: 0.34 - 1.55), and 1.62 (95% CI: 1.39 - 1.89) for inactivated vaccine, mRNA, vector, DNA, and protein subunit vaccines respectively. The pooled RR of local adverse event following immunization with inactivated vaccine, mRNA vaccine, vector vaccine, DNA vaccine, and protein subunit vaccine was 2.18 (95% CI: 1.32 - 3.59), 4.96 (95% CI: 4.02 - 6.11), 1.48 (95% CI: 0.88-2.50) 1.04 (95% CI: 0.12-8.75), and 4.09 (95% CI: 2.63-6.35) respectively.

CONCLUSION

mRNA vaccines are associated with greater risk of adverse events following immunization. However, at the present moment the benefits of all types of vaccines approved by WHO, still outweigh the risks of them and vaccination if available, is highly recommended.

摘要

背景

新冠病毒疫苗的高速接种引发了人们对新疫苗安全性的一些担忧。因此，对新冠病毒疫苗的安全性和有效性进行审查至关重要。

方法

检索了两个国际电子数据库（PubMed、ISI），以查找报告新冠病毒疫苗与对照组相比的疗效和安全性的临床试验。针对不同的疫苗类型，计算了接种后总不良反应、全身不良反应和局部不良反应的汇总风险比（RR）。

结果

灭活疫苗、mRNA 疫苗和载体疫苗的总不良反应发生率的汇总 RR 分别为 1.46（95%CI：1.19-1.78）、2.01（95%CI：1.82-2.23）和 1.65（95%CI：1.31-2.32）。不同疫苗类型接种后全身不良反应发生率的汇总 RR 分别为 1.13（95%CI：0.79-1.61）、1.53（95%CI 1.08-2.16）、1.58（95%CI：1.13-1.90）、0.72（95%CI：0.34-1.55）和 1.62（95%CI：1.39-1.89）。灭活疫苗、mRNA 疫苗、载体疫苗、DNA 疫苗和蛋白亚单位疫苗接种后局部不良反应的汇总 RR 分别为 2.18（95%CI：1.32-3.59）、4.96（95%CI：4.02-6.11）、1.48（95%CI：0.88-2.50）、1.04（95%CI：0.12-8.75）和 4.09（95%CI：2.63-6.35）。